Murray A. Raskind, M.D. | Psychiatrist.com

Article

Doxazosin XL for PTSD

May 25, 2016

One alpha-1 noradrenergic antagonist drug has shown promise in treating PTSD-related sleep disturbances and nightmares, but it has a short half-life. Could the long half-life version of this type...

Christopher Rodgman, Christopher D. Verrico, Manuela Holst, et al

Letter to the Editor

Dosing by Side Effect Threshold: Two Cases of Panic Disorder Responsive to Low-Dose Venlafaxine

January 15, 2010

Herbert Orenstein, Murray A. Raskind

Letter to the Editor

Beneficial Effects of Prazosin for Visual Hallucinations Associated With Chronic Cocaine Abuse

November 15, 2006

Andre M. Tapp, Annette Kennedy, Elaine R. Peskind, et al

Original Research

Prazosin Reduces Nightmares in Combat Veterans With Posttraumatic Stress Disorder

July 16, 2002

Murray A. Raskind, Charles Thompson, Eric C. Petrie, et al

Letter to the Editor

Reply to Letter to the Editor "Metrifonate for Alzheimer's Disease Patients"

August 31, 2000

Murray A. Raskind, Pamela A. Cyrus

Original Research

The ɑ1-Adrenergic Antagonist Prazosin Ameliorates Combat Trauma Nightmares in Veterans With Posttraumatic Stress Disorder: A Report of 4 Cases

July 31, 2000

Murray A. Raskind, Dorcas J. Dobie, Evan D. Kanter, et al

Article

Evaluation and Management of Aggressive Behavior in the Elderly Demented Patient

June 1, 1999

Murray A. Raskind

Original Research

The Effects of Metrifonate on the Cognitive, Behavioral, and Functional Performance of Alzheimer's Disease Patients

May 1, 1999

Murray A. Raskind, Pamela A. Cyrus, Bianca B. Ruzicka, et al

Article

Psychopharmacology of Noncognitive Abnormal Behaviors in Alzheimer's Disease

May 1, 1998

Murray A. Raskind

Article

The Clinical Interface of Depression and Dementia

March 1, 1998

Murray A. Raskind